This study aims to examine the effectiveness of serious game “Medi en Seintje” to improve medication adherence and clinical outcomes in patients with rheumatoid arthritis treated with Disease Modifying Anti-Rheumatic Drugs (DMARDs).
ID
Bron
Verkorte titel
Aandoening
Rheumatoid Arthritis
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
The primary outcome comprises the difference in proportion of non-adherent patients (less than 80% medication adherence) after three months in the intervention (serious game) group compared to usual care. Primarily, medication adherence will be measured using the Compliance Questionnaire for Rheumatology (CQR). The CQR presented good validity when compared to an electronic medication monitoring device over a period of six months [22]. Currently, the CQR is regarded as a reliable instrument to assess self-reported adherence in RA.
Achtergrond van het onderzoek
Country of recruitment: The Netherlands
SUMMARY
Rationale: Effectiveness of pharmacological therapy in inflammatory rheumatic diseases may be limited by inadequate patient adherence to medication. Interventions to improve adherence of DMARDs are therefore necessary to reduce undesirable effects of non-adherence on disease activity, joint damage and overall healthcare costs. Games are increasingly used to address behavioural and psychological factors associated with adherence to medical treatment regimens. Nevertheless, no serious game, where the main goal is providing entertainment, has ever been deployed to subtly and positively influence medication adherence behaviour.
Objective: This study aims to examine the effectiveness of serious game “Medi en Seintje” to improve medication adherence and clinical outcomes in patients with rheumatoid arthritis treated with Disease Modifying Anti-Rheumatic Drugs (DMARDs).
Study design: The effectiveness of this serious game will be assessed in a randomised clinical multicentre trial comparing the serious game intervention to traditional care.
Study population: Adults diagnosed with rheumatoid arthritis treated with Disease Modifying Anti-Rheumatic Drugs
Intervention (if applicable): The intervention group will be asked to install and play a puzzle game on their tablet or mobile phone. Playing the puzzle game is encouraged at the start of the study but otherwise completely voluntary.
Main study parameters/endpoints: The main study parameter is adherence. Primarily this is assessed using the validated Compliance Questionnaire for Rheumatology (CQR). Additionally, a pill count will be performed and the Beliefs About Medicine Questionnaire will be collected. Secondary clinical outcomes are the Health Assessment Questionnaire (HAQ) and the self-reported Rheumatoid Arthritis Disease Activity Index (RADAI). DAS-28 will be gathered if available. Lastly, game experience on the puzzle game will be assessed.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: It has been shown that merely measuring adherence already leads to an increase in adherence. An increase in medication adherence is likely to improve disease outcomes for patients. The intervention itself is voluntary, considered to be fun and no adverse events are to be expected. The burden for patients during a period of three months consists of a total of thirteen extra questionnaires.
Doel van het onderzoek
This study aims to examine the effectiveness of serious game “Medi en Seintje” to improve medication adherence and clinical outcomes in patients with rheumatoid arthritis treated with Disease Modifying Anti-Rheumatic Drugs (DMARDs).
Onderzoeksopzet
1 and 3 months
Onderzoeksproduct en/of interventie
Puzzle game 'Medi & Seintje' available on smartphone or tablet. Intervention patients can play at will.
Algemeen / deelnemers
Bart Pouls
Hengstdal 3
Ubbergen 6574 NA
The Netherlands
0031 24 327 2518
b.pouls@maartenskliniek.nl
Wetenschappers
Bart Pouls
Hengstdal 3
Ubbergen 6574 NA
The Netherlands
0031 24 327 2518
b.pouls@maartenskliniek.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
• diagnosis of RA (2010 ARA criteria [21] or clinical judgement by a rheumatologist);
• use at least one DMARD that is dosed weekly or more frequent (in other words: all oral DMARDs and biological DMARDs injected weekly);
• >18 years;
• sufficient ability to understand Dutch;
• be able to be followed for 3 months (life expectancy);
• in possession of smartphone/tablet.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
• cognitive and/or visual limitations that restrain the patient from playing the serious game (as assessed by the healthcare professional);
• assistance in taking drugs (e.g. home care);
• included in another trial.
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
Register | ID |
---|---|
NTR-new | NL7217 |
NTR-old | NTR7416 |
Ander register | CMO Arnhem - Nijmegen : 2018-4648 |